These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 19202702)

  • 1. Health economics: drug-eluting stents--are they worth the money?
    Gershlick AH; Fearn S
    EuroIntervention; 2008 Aug; 4 Suppl C():C75-9. PubMed ID: 19202702
    [No Abstract]   [Full Text] [Related]  

  • 2. NICE guidelines for the use of drug-eluting stents: how do we establish worth?
    de Belder MA;
    Heart; 2008 Dec; 94(12):1646-8. PubMed ID: 18728067
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry.
    Tamburino C; Barbagallo R; Capodanno D; di Matteo S; Colombo GL; Recchia M; Ciriminna S;
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):322-9. PubMed ID: 19430343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of drug-eluting stents compared to bare metal stents using a large prospective study in Ontario.
    Goeree R; Bowen JM; Blackhouse G; Lazzam C; Cohen E; Chiu M; Hopkins R; Tarride JE; Tu JV
    Int J Technol Assess Health Care; 2009 Apr; 25(2):196-207. PubMed ID: 19331710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007.
    Daemen J; Simoons ML; Wijns W; Bagust A; Bos G; Bowen JM; Braunwald E; Camenzind E; Chevaliers B; DiMario C; Fajadeto J; Gitt A; Guagliumi G; Hillege HL; James S; Jüni P; Kastrati A; Kloth S; Kristensen SD; Krucoff M; Legrand V; Pfisterer M; Rothman M; Serruys PW; Silber S; Steg PG; Tariah I; Wallentin L; Windecker SW; Aimonetti A; Allocco D; Berenger M; Boam A; Calle JP; Campo G; Carlier S; de Schepper J; Di Bisceglie G; Dobbels H; Farb A; Ghislain JC; Hellbardt S; ten Hoedt R; Isaia C; de Jong P; Lekehal M; LeNarz L; Mhullain FN; Nagai H; Patteet A; Paunovic D; Potgieter A; Purdy I; Raveau-Landon C; Ternstrom S; Van Wuytswinkel J; Waliszewski M;
    EuroIntervention; 2009 Jan; 4(4):427-36. PubMed ID: 19284063
    [No Abstract]   [Full Text] [Related]  

  • 6. Commentary on drug-eluting stents: NICE technology appraisal guidance.
    Richardson J; Stevens A; Barnett D; Longson C
    Heart; 2008 Dec; 94(12):1650-2. PubMed ID: 18768567
    [No Abstract]   [Full Text] [Related]  

  • 7. Commentary on drug-eluting stents: to use or not to use--that is the question!
    Pfisterer ME
    Heart; 2008 Dec; 94(12):1648-50. PubMed ID: 18782796
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug-eluting stents for the treatment of coronary artery disease: NICE technology appraisal guidance.
    Messori A; Trippoli S
    Heart; 2009 May; 95(10):847. PubMed ID: 19401286
    [No Abstract]   [Full Text] [Related]  

  • 9. How firms set prices for medical materials: a multi-country study.
    Ide H; Mollahaliloglu S
    Health Policy; 2009 Sep; 92(1):73-8. PubMed ID: 19342115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of drug-eluting stents and coronary artery bypass surgery for the treatment of multivessel coronary disease: three-year follow-up results from a single institution.
    Li Y; Zheng Z; Xu B; Zhang S; Li W; Gao R; Hu S
    Circulation; 2009 Apr; 119(15):2040-50. PubMed ID: 19349321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporal changes in coronary revascularization procedures, outcomes, and costs in the bare-metal stent and drug-eluting stent eras: results from the US Medicare program.
    Ryan J; Linde-Zwirble W; Engelhart L; Cooper L; Cohen DJ
    Circulation; 2009 Feb; 119(7):952-61. PubMed ID: 19204307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffusion of new technology and payment policies: coronary stents.
    Shih C; Berliner E
    Health Aff (Millwood); 2008; 27(6):1566-76. PubMed ID: 18997213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
    Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
    Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
    J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-eluting stent prices continue slow downward spiral. Price pressure mounts from adverse clinical findings, new competition.
    Hosp Mater Manage; 2008 Aug; 33(8):5-7. PubMed ID: 18754540
    [No Abstract]   [Full Text] [Related]  

  • 18. The problem of stent thrombosis associated with drug-eluting stents and the optimal duration of dual antiplatelet therapy.
    Ayyanathan S; Hersh D; Coplan NL; Garratt K
    Prev Cardiol; 2009; 12(2):59-64. PubMed ID: 19476578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Case for Value-Based Pricing of Corticosteroid-Eluting Sinus Stents.
    Rathi VK; Metson R; Scangas GA
    JAMA Otolaryngol Head Neck Surg; 2020 Mar; 146(3):221-222. PubMed ID: 31971551
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Outcomes of bare metal versus drug-eluting stents in allograft vasculopathy.
    Hiemann NE; Hetzer R; Fleck E; Wellnhofer E
    J Heart Lung Transplant; 2009 May; 28(5):531. PubMed ID: 19416788
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.